Irreversible alopecia universalis during treatment with pegylated interferon-ribavirin for chronic hepatitis C virus infection: Case report and published work review

Barbara Omazzi, Alberto Prada, Gianmario Borroni, Francesco Sacrini

Research output: Contribution to journalArticlepeer-review

Abstract

Hair disorders that have been described in association with pegylated interferon-ribavirin combination treatment include canities, hypertrichosis, telogen effluvium, and the most common cutaneous side-effect by far, alopecia. Alopecia is a heterogeneous disease characterized by hair loss on the scalp or any hair-bearing surface with a wide range of clinical presentations, from a single patch of hair loss to complete loss of hair on the entire body (alopecia universalis). Although some cases of reversible alopecia universalis associated with pegylated interferon-ribavirin combination therapy have been reported in the published work, irreversible alopecia universalis has not yet been reported in relation to pegylated interferon and ribavirin combination treatment. For the first time, we report a case of irreversible alopecia universalis during pegylated interferon-ribavirin combination therapy in a man infected with hepatitis C virus in the absence of clinical or biochemical evidence of immunological disorders or thyroid dysfunction at any time before, during or after antiviral therapy.

Original languageEnglish
Pages (from-to)1248-1251
Number of pages4
JournalHepatology Research
Volume42
Issue number12
DOIs
Publication statusPublished - Dec 2012

Keywords

  • Hepatitis C
  • Irreversible alopecia universalis
  • Side-effects
  • Treatment

ASJC Scopus subject areas

  • Hepatology
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Irreversible alopecia universalis during treatment with pegylated interferon-ribavirin for chronic hepatitis C virus infection: Case report and published work review'. Together they form a unique fingerprint.

Cite this